Alzheimer’s disease is a progressive brain disorder that slowly destroys memory, thinking skills, and eventually the ability to carry out basic daily tasks. It is the most common type of dementia, accounting for 60% to 80% of all dementia cases. An estimated 7.4 million Americans age 65 and older live with Alzheimer’s today, and that number is projected to nearly double by 2060.
Dementia vs. Alzheimer’s Disease
Dementia is not a single disease. It’s an umbrella term for a decline in mental ability severe enough to interfere with daily life. Alzheimer’s is one specific cause of dementia, and by far the most common one. Other types include vascular dementia (caused by reduced blood flow to the brain), Lewy body dementia, and frontotemporal dementia. When someone receives a dementia diagnosis, the next step is identifying which type is responsible, because each has different causes, trajectories, and treatment options.
What Happens in the Brain
Two types of abnormal protein buildup drive Alzheimer’s. The first involves a protein fragment called amyloid-beta, which clumps together outside brain cells to form sticky plaques. Before those plaques fully form, smaller clusters of amyloid-beta (called oligomers) float between neurons and are considered the most directly toxic form. These clusters damage the connections between brain cells, disrupting the signals that underlie memory and thought.
The second involves a protein called tau, which normally helps maintain the internal scaffolding that neurons rely on to transport nutrients and chemical signals. In Alzheimer’s, tau becomes chemically altered, detaches from that scaffolding, and tangles into insoluble knots inside the neuron. These neurofibrillary tangles block the cell’s internal transport system, starving it of what it needs to function. Over time, the neuron dies.
These two processes don’t operate independently. Amyloid-beta and tau act together to damage synapses, the junctions where brain cells communicate. Their combined presence can silence entire neural circuits, which is why cognitive decline accelerates as both pathologies spread through the brain.
Symptoms by Stage
Alzheimer’s progresses through roughly three stages, though the boundaries between them blur and the pace varies widely from person to person.
Early Stage (Mild)
The earliest noticeable signs often look like ordinary forgetfulness: missing appointments, losing track of recent conversations, misplacing keys or a wallet. What distinguishes this from normal aging is the pattern and frequency. People in early-stage Alzheimer’s may struggle to judge how long a task will take, have difficulty organizing the steps needed to complete something, or find it harder to make sound decisions. Motivation to finish tasks often drops. Finding the right word during conversation becomes noticeably more difficult, and getting lost in familiar places starts to happen.
Middle Stage (Moderate)
This is typically the longest stage and the one where most families first seek help. Memory gaps widen to include significant personal history. Confusion about the day, season, or location becomes common. People may need help choosing appropriate clothing, managing finances, or following a recipe they once knew by heart. Personality changes often emerge: increased irritability, suspicion of others, or withdrawal from social situations. Wandering and getting lost outside the home becomes a real safety concern.
Late Stage (Severe)
In advanced Alzheimer’s, individuals lose the ability to respond to their environment, carry on a conversation, or control movement. They may still speak words or phrases but can no longer communicate meaningfully. Swallowing becomes difficult. Round-the-clock care is needed for all daily activities. At this stage, the body becomes increasingly vulnerable to infections, particularly pneumonia, which is a common cause of death.
Risk Factors
Age is the single biggest risk factor. The vast majority of people with Alzheimer’s are 65 or older, and risk rises steeply after 85. But age alone doesn’t cause the disease.
Genetics play a significant role. The most well-studied genetic risk comes from a variant of the APOE gene called e4. Carrying one copy of APOE-e4 doubles or triples the risk of developing Alzheimer’s. Carrying two copies raises the risk 8 to 12 times. Still, many people with the e4 variant never develop the disease, and many without it do.
A landmark 2024 report from The Lancet Commission identified 14 modifiable risk factors that collectively account for a substantial share of dementia cases worldwide. These include less education, hearing loss, high blood pressure, smoking, obesity, depression, physical inactivity, diabetes, excessive alcohol consumption, traumatic brain injury, air pollution, social isolation, untreated vision loss, and high LDL cholesterol. The last two were newly added based on growing evidence. None of these guarantees or prevents Alzheimer’s on their own, but addressing them meaningfully lowers overall risk.
How Alzheimer’s Is Diagnosed
Diagnosis typically begins with cognitive testing, a detailed medical history, and brain imaging to rule out other causes like stroke or tumors. For years, a definitive Alzheimer’s diagnosis could only be confirmed after death through brain autopsy. That is changing.
Specialized PET scans can now visualize amyloid plaques in a living brain using radiolabeled tracers that bind to the protein deposits. Spinal fluid tests measure levels of amyloid-beta and tau proteins directly, with specific ratios that indicate Alzheimer’s pathology. These tools are primarily used in specialty clinics and research settings, but they’ve transformed the ability to confirm a diagnosis with confidence.
Perhaps the most promising shift is the development of blood tests. A test measuring a specific form of tau protein (p-tau217) has been validated in outpatient memory clinics with 95% sensitivity and 82% specificity, meaning it correctly identifies the vast majority of people who have Alzheimer’s and rules out most of those who don’t. Blood tests like this could eventually make early, accurate diagnosis available in any doctor’s office rather than requiring expensive scans or spinal taps.
Treatment Options
For decades, Alzheimer’s medications could only manage symptoms without touching the underlying disease. Drugs that boost chemical signaling between surviving neurons still help with memory and thinking in some patients, but they don’t slow the progression.
A new class of treatments now targets amyloid plaques directly. These are antibody-based infusions designed to clear the toxic protein from the brain. Two have received FDA approval for early-stage Alzheimer’s.
Lecanemab (sold as Leqembi) targets the smaller, soluble clumps of amyloid-beta before they fully aggregate into plaques. In its Phase 3 trial, it slowed cognitive decline by 27% over 18 months compared to placebo and reduced amyloid plaque levels by roughly 59 centiloids on PET imaging, a substantial drop.
Donanemab (sold as Kisunla) takes a different approach, binding specifically to amyloid that has already formed into dense plaques and triggering the brain’s immune cells to engulf and clear them. In its Phase 3 trial, donanemab slowed decline by about 35% on a standard measure of cognition and daily function. Its effect on plaques was dramatic: approximately 80% of treated patients achieved complete amyloid clearance on PET scans by the end of the 18-month trial.
These treatments are not cures. They slow the rate of decline but don’t stop it. They also carry a notable risk of brain swelling or small brain bleeds, particularly in people who carry the APOE-e4 gene variant. Both treatments are approved only for people with mild cognitive impairment or early-stage Alzheimer’s who have confirmed amyloid pathology, making accurate diagnosis more important than ever.
The Broader Impact
Alzheimer’s is the seventh leading cause of death in the United States, responsible for over 116,000 deaths annually. Unlike heart disease and many cancers, where death rates have declined with better treatments, Alzheimer’s mortality continues to climb as the population ages. The number of new cases per year is projected to double by 2050, driven largely by the growing population of adults over 85.
The toll extends well beyond the person diagnosed. Most Alzheimer’s care is provided by unpaid family members, often for years, with significant physical, emotional, and financial costs. The disease’s long duration, typically 4 to 8 years after diagnosis but sometimes as long as 20, means caregiving demands compound over time in ways that few other illnesses require.